ArticleBMC medicine2025
Proteomics and metabolomics studies in pigmented villonodular synovitis uncover the regulation of monocyte differentiation by the ADGRE5-NF-κB pathway.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expression of Molecular Markers Associated with Tenosynovial Giant Cell Tumours and Bone Destruction: A Systematic Review.Journal of clinical medicine · 2026Review
- Integrated multi-omics and machine learning identify an interaction between SLC39A11 and phosphoinositide metabolism in deep vein thrombosis.BMC medical informatics and decision making · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPigmented villonodular synovitis (PVNS), or tenosynovial giant cell tumor (TGCT), is a locally aggressive soft tissue tumor primarily affecting the synovium of joints, particularly the knee. In PVNS, the synovial tissue thickens and becomes aggressive, leading to joint destruction, a process reminiscent of the tissue remodeling seen in autoimmune diseases. Despite being considered benign, PVNS often leads to severe joint damage and has a high recurrence rate following treatment. The underlying molecular mechanisms of PVNS remain poorly understood, necessitating further research to uncover its pathogenesis and identify potential therapeutic targets. This study aims to investigate the pathological mechanisms of PVNS, focusing on the role of metabolic pathways, immune cell infiltration, and osteoclast differentiation in the progression of the disease.
methodsSynovial fluid samples from PVNS patients were subjected to high-throughput proteomic and metabolomic analyses. Differentially expressed proteins (DEPs) and metabolites were identified, and pathway enrichment analysis was performed. Western blot validation and two-way orthogonal partial least squares (O2PLS) analysis confirmed key findings and explored the relationships among identified biomarkers.
resultsA total of 156 DEPs and 62 differential metabolites were identified. The "Osteoclast differentiation signalling" and "Nuclear factor-κB (NF-κB) survival signalling" pathways were significantly upregulated in PVNS samples, with Tumor Necrosis Factor Superfamily Member 11 (TNFSF11), Cathepsin K (CTSK), Adhesion G Protein-Coupled Receptor E5 (ADGRE5), and NF-κB showing marked increases in expression. Metabolomic analysis revealed that "Linoleic acid metabolism" and "Biosynthesis of unsaturated fatty acids" pathways were enhanced in PVNS, with metabolites such as 13-L-Hydroperoxylinoleic acid and 13-OxoODE being highly expressed. Western blot validation confirmed the elevated levels of ADGRE5, TNFSF11, CTSK, and NF-κB, suggesting a link between enhanced energy metabolism, lipid oxidation, and osteoclast differentiation.
conclusionsThis study highlights the critical role of metabolic adaptations and immune cell activity in the progression of PVNS. The findings suggest that targeting ADGRE5 and NF-κB could offer new therapeutic strategies for controlling disease progression and reducing joint destruction in PVNS patients. Further research is needed to elucidate this disease's specific regulatory mechanisms and cell types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.